 |
      
|
|
|
|
|
|||||
|
|
November 13, 2001
Neurochem's data show early inflammation response during amyloid deposition in
Alzheimer's Disease model. Presentation at 31st Society for Neuroscience Annual Meeting in San Diego
New: SFN Poster available.
About the Study
The presentation, entitled "Early Inflammatory Response During Amyloid Deposition in
TgCRND8 Mice," utilizes a transgenic animal model harboring a mutant form of the human
amyloid precursor protein (hAPP) developed by the University of Toronto and used by
Neurochem. This model was used to determine the onset of amyloid-induced inflammation in
the brain during the process of amyloid fibrillogenesis. Inflammation, in addition to
amyloid plaque build-up, has been heavily implicated in the development of Alzheimer's
Disease. This study sought to determine whether inflammation precedes, coincides or follows
amyloid plaque formation. Conducted by Neurochem scientists in conjunction with
researchers from McGill University in Montreal and the Centre for Research in
Neurodegenerative Diseases at the University of Toronto, the study showed significant
evidence that inflammation occurs early on in the development of brain amyloidosis and may
precede the formation of aggregated plaques. About GAG Mimetics
Neurochem's innovative core technology, GAG Mimetics, consists of the design and synthesis
of compounds that mimic the properties of sulphated glycosaminoglycans' (GAGs) complex
carbohydrates that promote the amyloid fibril formation and deposition that is characteristic
of Alzheimer's Disease. About Neurochem
Neurochem is an industry leader in the development of therapeutic drugs and diagnostic tools
for central nervous system and amyloid-related diseases associated with aging. The Company
has built a strong product pipeline by developing a novel, proprietary series of compounds
that inhibit the formation, deposition and toxic effects of amyloid fibrils within the
body. Neurochem's therapeutic programs target Alzheimer's Disease, Epilepsy, Systemic
Amyloidosis, Diabetes Type II and Hemorrhagic Stroke (due to Cerebral Amyloid Angiopathy).
Neurochem is using a multi-pronged approach towards the development of pharmaceuticals
for Alzheimer's Disease, including glycosaminoglycans (GAGs) mimetics, a vaccine, an
anti-inflammatory and a neuroprotective approach as well as the creation of a diagnostic
imaging tool. The Company has advanced to date three drug candidates to clinical trials:
Alzhemed™, for the treatment of Alzheimer's Disease, Fibrillex™, for the orphan
disease Secondary Amyloidosis, and Cerebril™, for Hemorrhagic Stroke. At present,
the Company employs over 70 people and is located in Saint-Laurent, Canada
(www.neurochem.com).
All of the statements contained in this news release, other than statements of fact which
are independently verifiable at the date hereof, are forward-looking statements. Such
statements, based as they are on the current expectations of management, inherently involve
numerous risks and uncertainties, known and unknown. Some examples of known risks are: the
impact of general economic conditions, general conditions in the pharmaceutical industry, changes
in the regulatory environment in the jurisdictions in which Neurochem does business, stock
market volatility, fluctuations in costs, and changes to the competitive environment due to
consolidation or otherwise. Consequently, actual future results may differ materially from
the anticipated results expressed in the forward-looking statements.
For further Information, please contact: |
 |
|
 |
|
Our site is best viewed with IE4+ at a resolution of 1024×768. |
|
